Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
about
Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinomaAdjuvant therapy for resected pancreatic cancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Pancreatic cancer from bench to bedside: molecular pathways and treatment optionsA systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinomaBiomarkers and Targeted Therapy in Pancreatic CancerPerioperative treatment options in resectable pancreatic cancer - how to improve long-term survivalNeoadjuvant radiotherapeutic strategies in pancreatic cancerManagement of pancreatic cancer in the elderlyViro-immune therapy: A new strategy for treatment of pancreatic cancerAdjuvant therapy for pancreas cancer in an era of value based cancer careSurgery for oligometastasis of pancreatic cancerPerspectives in the treatment of pancreatic adenocarcinomaAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsNovel adjuvant therapies for pancreatic adenocarcinomaLaparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable?Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesMicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?Perioperative Therapy for Surgically Resectable Pancreatic AdenocarcinomaMolecular landscape of pancreatic cancer: implications for current clinical trialsImaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted NanovesiclesNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesPancreatic adenocarcinoma: treating a systemic disease with systemic therapyPerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerPancreatic Cancer, A Mis-interpreter of the Epigenetic LanguageNew challenges in perioperative management of pancreatic cancerAdvances in chemotherapy for pancreatic cancerUpdate on the management of pancreatic cancer: surgery is not enoughA Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer.Pancreatic cancer: yesterday, today and tomorrow.K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis.Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I studyPhase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.Adjuvant therapy in biliary tract and gall bladder carcinomas: a review.Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Ductal pancreatic adenocarcinoma.Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.Chemotherapy and tumor microenvironment of pancreatic cancer.
P2860
Q24186132-4F016B05-9E2F-429F-9773-16390DFA890DQ24186323-C522F4AE-8CF7-46E4-9AD8-A61298D5C42EQ26746031-EE634178-8A41-4DD3-B205-7D9360DB6BA6Q26747524-41EB6312-290D-40AE-873E-6D816177B77FQ26748880-2BAED3C8-DCE2-4D62-994D-57A5860D19C1Q26752755-1852ADFC-5CAC-436B-BEE1-B3EA2E7530B4Q26753854-79ED46DA-96CA-4D78-9E27-021D19C784ADQ26766686-3BA2D666-D56E-4AD5-A840-F5A7C876CDC6Q26774639-6EFBC857-B872-413E-A925-9EF9BE2CBD59Q26774641-0A607A00-F510-4182-BA0C-307CA784E72FQ26775916-7EAB2135-0281-4D86-BFFA-6D03F3D821F5Q26781546-C19A8C7F-631D-4FE8-B4DF-76E0A32E7EF7Q26797248-77C09FD3-A6B5-4F55-8933-86F671C0E19AQ26798674-DC5F33FB-2A61-467E-8729-246FF7AB3AF2Q26799425-8AD6C3FE-78CB-4470-8C1A-4C80D0649E8BQ26799434-9CABA070-B36F-4E49-9462-28BA51E58668Q26799714-4B55CC32-169E-4BBD-8DEC-1C27C7258889Q26799779-A6F1F56F-4112-41B6-8B3A-1B46DFF986E7Q26801411-AAFD9A9B-7B9E-4760-8A7D-5A4384611659Q26824528-9DD40B6C-A9BA-4A71-8F34-3EB40F94222DQ26828959-34FCCBE2-695F-4407-91BF-807CBA5AC1C1Q27004292-ECEFC45D-472B-4EF7-BE64-B9B970CB8CFDQ27008346-D9F2BE4E-6006-44DD-A12F-CF85806D1ABBQ28066320-FAF4BE64-DDCB-404B-8A1C-FECB259872F8Q28079735-FBE5BDCF-27F8-400D-9FEB-C63FBBB71F9DQ28082422-9B2043EE-C1EA-404D-ACF5-EF157887686AQ28085711-F397DDC8-52A4-495F-B8BF-9350FEA2C5C3Q28087060-2A5EE6E5-3DD6-455B-BAFB-BF668442FE83Q30238706-D629ECC3-AB14-4FC8-9EEE-E197FC69A5C4Q30249814-308E2840-4E2C-4CB2-9B38-98E83763CEE0Q30250026-B21BA21C-514D-47EC-BEFA-86AC920F4EF1Q30250097-8637BA0C-8758-428D-9B99-512EDE38811FQ30277400-B0A3C5D3-F1B6-40C7-B42E-F977B58F7F9FQ33417372-A61949C0-6A89-4B67-A900-E65E4C79E916Q33431711-8755B69E-B490-40AA-9B2F-80C03DA199CFQ33593250-A3BAF29E-0E63-410F-83CC-5F115B2D43E9Q33665450-AAF9C69A-0466-43EA-AD07-1A5754A4A589Q33832655-9FB36113-3D75-4034-9498-B6D35EEEF449Q33874242-1EE5CB23-FDA5-488C-AE39-46D1168ED984Q33876637-BF4C2EB2-6A43-4783-BDF2-06B31703A019
P2860
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adjuvant chemotherapy with gem ...... he CONKO-001 randomized trial.
@en
type
label
Adjuvant chemotherapy with gem ...... he CONKO-001 randomized trial.
@en
prefLabel
Adjuvant chemotherapy with gem ...... he CONKO-001 randomized trial.
@en
P2093
P50
P356
P1476
Adjuvant chemotherapy with gem ...... he CONKO-001 randomized trial.
@en
P2093
Axel Hinke
Carl Zülke
Hanno Riess
Helmut Oettle
Jörg Fahlke
Jörg Thomas Hartmann
Karsten Ridwelski
Klaus Gellert
Marianne Sinn
Michael B Arning
P304
P356
10.1001/JAMA.2013.279201
P407
P577
2013-10-01T00:00:00Z